Vistin Pharma ASA : First quarter 2017 results
(WorldNews Norway)

Oslo, Norway, 26 April 2017 Norwegian pharmaceutical company Vistin Pharma ASA (OSE: VISTIN) recorded strong sales volumes for the first quarter of 2017 for both its metformin and opioid products. A dividend of NOK 1.00 per share for 2016 has been proposed by the Board of Directors, which is an increase from NOK 0.60 per share for 2015. Vistin Pharma recorded total revenues of NOK 97.3 million in the first quarter of 2017, compared to NOK 103.2 million in the first quarter of 2016. An eight percent increase in sales volume for metformin was more than offset by a shift in the product portfolio balance towards more...